---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-055411"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:18:05.951589+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ocugen posts Q1 loss, details positive Phase 2 GA data, prices $115M notes

## Summary
- Net loss of $(0.06) per share for Q1 2026; cash, cash equivalents, and restricted cash of $32.2M as of March 31, 2026.
- Phase 2 OCU410 trial for GA showed statistically significant 31% reduction in lesion growth at 12 months with optimal dose; 20% of patients showed no progression.
- Enrollment completed for OCU400 Phase 3 RP trial (N=140) and OCU410ST Stargardt Phase 2/3 trial (N=63); BLA submissions targeted by 2027.
- Priced $115M (up to $130M with over-allotment) of 6.75% Convertible Senior Notes due 2034 at 90% of par; conversion premium of 45% at $2.68/shr.
- Net proceeds ~$99.5M; $32.7M to repay Avenue debt (12.5% interest); expected to extend cash runway into 2028.

## SEC filing metadata
- accession: 0001104659-26-055411
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000110465926055411/0001104659-26-055411-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000110465926055411/tm2613584d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-055411
- JSON: https://secwatch.observer/filing/0001104659-26-055411.json
- Plain text: https://secwatch.observer/filing/0001104659-26-055411.txt

## Source-grounded claims
- claim_id: c87151e6c03eed4a7668845a844b8bf31015fd0e
  claim: Ocugen, Inc. reported financial results for quarter ended March 31, 2026.
  evidence_excerpt: On May 5, 2026, Ocugen, Inc (the “Company”) issued a press release announcing certain financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372299/000110465926055411/0001104659-26-055411-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.